Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL544287 | 0.83 | POLB (0.61) | POLBNPBWR1MCHR1KDM4EMEN1 | |
| SCHEMBL1247688 | 0.82 | POLB (0.64) | POLBTP53KDM4EMEN1KMT2A | |
| SCHEMBL9459015 | 0.78 | KDR (0.51) | POLBTP53CYP3A4KDM4ENPSR1 | |
| SCHEMBL1491128 | 0.77 | POLB (0.53) | POLBCYP3A4NPSR1 | |
| SCHEMBL15428758 | 0.76 | POLB (0.57) | POLBKDM4EMEN1KMT2ANPC1 | |
| SCHEMBL15428658 | 0.76 | POLB (0.57) | POLBNPBWR1MCHR1TP53CYP3A4 | |
| SCHEMBL406516 | 0.74 | ALDH1A1 (0.41) | NPBWR1MCHR1KDM4ENPSR1MEN1 | |
| SCHEMBL433371 | 0.72 | POLB (1.00) | POLBTP53CYP3A4KDM4ENPSR1 | |
| SCHEMBL1491136 | 0.72 | POLB (0.69) | POLBCYP3A4KDM4ENPSR1MEN1 | |
| SCHEMBL15428572 | 0.72 | POLB (0.43) | POLBTP53CYP3A4KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435068-B2 | Anthelmintic compounds | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-10-07 | — | — | US | disclosed |
| CN-119409690-A | Novel insect repellent compound | 拜耳动物保健有限责任公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20210380566-A1 | NEW ANTHELMINTIC COMPOUNDS | ELANCO ANIMAL HEALTH GMBH (DE) | 2021-12-09 | — | — | US | disclosed |
| US-20210380566-A1 | NEW ANTHELMINTIC COMPOUNDS | ELANCO ANIMAL HEALTH GMBH (DE) | 2021-12-09 | — | — | US | disclosed |
| CN-113166123-A | Novel insect repellent compounds | 拜耳动物保健有限责任公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3847168-A2 | NEW ANTHELMINTIC COMPOUNDS | Bayer Animal Health GmbH (DE) | 2021-07-14 | — | — | EP | disclosed |
| EP-3643711-A1 | NEW ANTHELMINTIC COMPOUNDS | Bayer Animal Health GmbH (DE) | 2020-04-29 | — | — | EP | disclosed |
| EP-3643711-A1 | NEW ANTHELMINTIC COMPOUNDS | Bayer Animal Health GmbH (DE) | 2020-04-29 | — | — | EP | disclosed |
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| EP-2962566-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-2348860-B1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH INC (US) | 2015-05-27 | — | — | EP | disclosed |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8637526-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | POLB 2697/4885NPBWR1 1932/4885MCHR1 1910/4885 |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | POLB 2697/4885NPBWR1 1932/4885MCHR1 1910/4885 |
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | POLB 2697/4885NPBWR1 1932/4885MCHR1 1910/4885 |
| US-12435068-B2 | Anthelmintic compounds | H1-10, HRH2, HRH1 | POLB 4008/4885NPBWR1 1835/4885MCHR1 913/4885 |
| US-20210380566-A1 | NEW ANTHELMINTIC COMPOUNDS | H1-10, HRH2, HRH4 | POLB 3969/4885NPBWR1 1774/4885MCHR1 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.